ReviewFrontiers in immunology2020
Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.Liver cancer · 2026Review
- Targeting circulating mechanoresponsive monocytes and macrophages to reduce fibrosis.Nature biomedical engineering · 2026Article
- Spatial omics insights into tumor myeloid cells: roles in tumorigenesis, prognosis, and therapy.Molecular biology reports · 2026Review
- Decoding myeloid heterogeneity in glioblastoma: spatial insights from transcriptomics.Journal of translational medicine · 2026Review
- Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review.American journal of physiology. Heart and circulatory physiology · 2025Review
- Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma.JCI insight · 2025Article
- Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.Molecular cancer · 2024Review
- CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.Cell reports · 2024Article
- Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design.iScience · 2023Article
- Deciphering the tumour immune microenvironment cell by cell.Immuno-oncology technology · 2023Review
- Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma.Cancer science · 2023Article
- Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy.International journal of nanomedicine · 2023Review
- Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.Frontiers in oncology · 2023Review
- Impact of Cuproptosis-related markers on clinical status, tumor immune microenvironment and immunotherapy in colorectal cancer: A multi-omic analysis.Computational and structural biotechnology journal · 2023Article
- CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.Science advances · 2022Article
- The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells.Frontiers in immunology · 2022Review
- Modelling the tumor immune microenvironment for precision immunotherapy.Clinical & translational immunology · 2022Review
- Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.Frontiers in immunology · 2022Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Tumor-mediated regulation of the host immune system involves an intricate signaling network that results in the tumor's inherent survival benefit. Myeloid cells are central in orchestrating the mechanisms by which tumors escape immune detection and continue their proliferative programming. Myeloid cell activation has historically been classified using a dichotomous system of classical (M1-like) and alternative (M2-like) states, defining general pro- and anti-inflammatory functions, respectively. Explosions in bioinformatics analyses have rapidly expanded the definitions of myeloid cell pro- and anti-inflammatory states with different combinations of tissue- and disease-specific phenotypic and functional markers. These new definitions have allowed researchers to target specific subsets of disease-propagating myeloid cells in order to modify or arrest the natural progression of the associated disease, especially in the context of tumor-immune interactions. Here, we discuss the myeloid cell contribution to solid tumor initiation and maintenance, and strategies to reprogram their phenotypic and functional fate, thereby disabling the network that benefits tumor survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.